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Background and aims: Hemodialysis patients have an enhanced risk for cardiovascular events.
Cardiac biomarkers provide useful information for stratifying their risk. However the prog-
nosis  value of creatine kinase MB isoenzyme (CKMB) has not yet been validated in this
population. The aim of the present study is to determine the predictable value of CK-MB in
hemodialysis.
Methods: A cohort of 211 hemodialysis patients (58.3% male, median age 73 (60–80) years)
were  followed for 39 (19–56) months. Cardiac biomarkers including CKMB were recorded at
baseline. Factors associated to CKMB and prognosis value of this biomarker was studied.
Results: The median value of CKMB was 1 (1–2) ng/mL with no patient exceeding normal
laboratory values. Previous heart disease, diabetes mellitus, peripheral vascular disease and
systolic and diastolic dysfunction were associated with higher levels of CKMB. Ninety-four
patients (44.5%) cardiovascular events were recorded. CKMB levels ≥2 ng/mL was indepen-
dently associated to cardiovascular events during the follow up after adjusting. Adding
CKMB to a model including several variables for predicting cardiovascular events, resulted
in  17% improvement in risk discrimination (IDI) with a relative IDI of 9.9% (p = 0.04).
Conclusions: CKMB is a good marker for stratifying cardiovascular risk in hemodialysis
patients and adds prognosis information to other well known independent predictors for
cardiovascular events.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Creatincinasa  y  pacientes  en  diálisis,  ¿una  herramienta  útil  para
estratiﬁcar  el  riesgo  cardiovascular?
r  e  s  u  m  e  nalabras clave:
iomarcadores cardiacos
ardiovascular
Antecedentes y objetivos: Los pacientes en hemodiálisis presentan un riesgo cardiovascular
elevado. Los biomarcadores cardiacos otorgan información útil para estratiﬁcar dicho riesgo
cardiovascular. Sin embargo, el valor pronóstico de la isoenzima MB de la creatincinasa
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CKMB
Hemodiálisis
(CKMB) no ha sido aún validado en esta población. El objetivo del presente trabajo es evaluar
el  valor predictivo de CKMB en una población en hemodiálisis.
Métodos: Una cohorte de 211 pacientes en hemodiálisis (58,3% varones, con una edad media
de  73 [60–80] an˜os) fueron seguidos durante 39 (19–56) meses. Se recogieron basalmente los
valores de diferentes biomarcadores cardiacos incluyendo CKMB. Se evaluaron los factores
asociados a niveles más elevados de CKMB, así como su valor predictivo independiente.
Resultados: La mediana de CKMB fue de 1 (1–2) ng/mL. Todos los pacientes presentaron val-
ores  dentro de los establecidos de referencia en la población normal. Los antecedentes de
cardiopatía, diabetes mellitus, enfermedad periférica y la disfunción diastólica y sistólica
se  asociaron a niveles más elevados de CKMB. Un total de 94 pacientes (44,5%) presen-
taron  un evento cardiovascular. Los niveles de CKMB ≥ 2 ng/mL se asociaron de manera
independiente a presentar eventos cardiovasculares durante el seguimiento tras el ajuste
para diferentes factores. La adición de CKMB a un modelo predictor con diferentes factores
generó una mejoría del 17% en la estimación de la probabilidad de forma lineal (IDI) con un
IDI  relativo del 9,9% (p = 0,04).
Conclusiones: CKMB es un buen marcador para estratiﬁcar el riesgo cardiovascular en los
pacientes de hemodiálisis y an˜ade información en cuanto al pronóstico cuando se combina
con otros predictores de eventos cardiovasculares.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-NDIntroduction
Chronic kidney disease (CKD) is a major cardiovascular
risk factor similar to congestive heart failure, and this risk
increases with the decline of renal function, being maximum
in dialysis.1,2
Several strategies have been proposed in order to detect
those patients at high risk for developing cardiovascular
events and for detecting subclinical alterations to be treated.3
Current guidelines recommend measuring cardiac biomark-
ers, speciﬁcally troponins and natriuretic peptides, as they are
usually increased in our patients.1,4 If possible, ecocardiogra-
phy should be performed periodically although recommended
intervals vary in function of the guideline. Some studies have
found a strong association between cardiac biomarkers, eco-
cardiographic ﬁndings and prognosis.3,5
On one hand, serum cardiac biomarkers are increased in
virtually all CKD patients especially in dialysis and those who
have higher values have poorer prognosis. On the other hand,
when these biomarkers are adjusted by ecocardiographic ﬁnd-
ings (for example, diastolic and systolic dysfunction and left
ventricular hypertrophy) they lose their independent predic-
tion value, suggesting their role as observer of cardiac damage,
usually subclinically.5,6 Most importantly, increased cardiac
biomarkers seems to be universal with high sensitivity assays,
but those with higher values have a better association to
postmortem cardiac damage or with coronary lesions demon-
strated by angiography.7,8
However, and although several authors have proposed dif-
ferent cut-offs for stratifying the cardiovascular risk, lack of
agreement has been reached, suggesting that probably those
markers must be interpreted as continuous variables.
One important biomarker has not been widely studied
in CKD patients until date, creatine kinase MB  isoenzyme
(CKMB). In general population, its sensitivity in acute coro-
nary syndromes is inferior to troponins. However, due to its(http://creativecommons.org/licenses/by-nc-nd/4.0/).
small half-life, current guidelines recommend its use for mon-
itoring cardiac damage after revascularization as they present
a good correlation with re-infarction.9,10 Many patients with
CKD have been excluded from studies about CKMB due to its
difﬁcult interpretation when renal function is impaired. Pub-
lished series yield controversial data in terms of prevalence
of raise serum values and their use in ischemic heart disease.
However, it seems to have the same value as prognosis marker
in re-infarction in patients with renal impairment.11,12 The
aim of the present study was to analyze the prognosis value
of CKMB in a cohort of dialysis patients and also its related
factors.
Materials  and  methods
Patients
A total of 211 patients on hemodialysis in a single center
were enrolled in the restrospective study. Stable patients with
no cardiovascular events in the 4 weeks before serum deter-
minations were included. During the follow up [39 (19–56)
months], patients with changes in hemodialysis parameters,
transferred to another center or transplanted were censored.
Investigations were in accordance with the Declaration of
Helsinki.
Baseline  characteristics  and  measurements
Baseline characteristics were recorded, including age, sex,
presence of diabetes mellitus, peripheral vascular disease,
previous cardiovascular disease (congestive heart failure
determined by echocardiography within the three previous
months, myocardial infarction, cerebrovascular disease), dial-
ysis vintage and data regarding the vascular access. Basally,
we measured C-reactive protein (CRP), high sensitivity tro-
ponin T (hsTnT), CK-MB and N-terminal prohormone of brain
 0 1 6;
n
t
w
s
H
l
E
E
a
w
m
a
E
o
t
A
a
v
f
O
N
b
i
l
f
d
S
V
W
d
e
m
c
w
p
o
C
C
c
w
w
d
e
a
h
N
m
d
t
r
i
i
b
p = 0.020) and between NtproBNP and HsTnT (0.635, p < 0.001).
No signiﬁcant correlation was established between CKMB and
HsTnT.
Table 1 – Baseline characteristics.
Age (years) 73 (60-80)*
Sex male, n (%) 123 (58.3)a
History of heart disease, n (%) 90 (42.7)a
Diabetes mellitus, n (%) 68 (32.2)a
Peripheral vascular disease, n (%) 64 (30.3)a
Previous echocardiogram, n (%) 166 (78.7)a
- Left ventricular hypertrophy, n (%) 106 (63.9)a
- Systolic dysfunction, n (%) 24 (14.4)a
- Diastolic dysfunction, n (%) 60 (36.1)a
Previous dialysis vintage (months) 83 (43-128)*
Vascular access
- Autologous n (%)
- PTFE n (%)
- Permanent catheter n (%)
116  (55)a
65 (31)a
30 (14)a
HsTnT (ng/L) 56 (35-90)*
CKMB (ng/mL)
- 0 ng/mL,n (%)
- 1 ng/mL,n (%)
- 2 ng/mL,n (%)
- 3 ng/mL,n (%)
- 4 ng/mL,n (%)
1  (1-2)*
13 (6.3)a
121 (58.5)a
56 (27.1)a
13 (6.3)a
4 (1.9)a
Nt-proBNP (ng/L) 4994 (2237-15036)*
CRP (mg/L) 7.0 (4.0-15.0)*
an e f r o l o g i a 2
atriuretic peptide (Nt-proBNP). All included patients had
he same hemodialysis therapy protocol: 4 h, three times per
eek. Routine clinical and biochemical variables were mea-
ured by standardized methods on autoanalyzers. CKMB and
sTnT were measured on a Roche/Hitachi Cobas E411 ana-
yzer. Factors related to higher values of CKMB were analyzed.
chocardiography
chocardiography was recorded in stable patients who had
 less than 6-month one before obtaining the sample and
ithin 24 h after the last hemodialysis on the day between
id-week dialysis sessions. Diastolic dysfunction was deﬁned
s e′ (early mitral annulus velocity) less than 8 cm/s, average
 (early mitral ﬂow)/e′ over 8, LAVi (left atrium volume index)
ver 28 mL/m2 or Ar − A (time difference between duration of
he pulmonary venous atrial reversal wave  and duration of the
 wave)  over 30 ms.  Systolic dysfunction in turn was deﬁned
s a left ventricle ejection fraction of under 45%. The left
entricular mass index (LVMi) was estimated by Devereux’s
ormula.13
utcomes
ew cardiovascular events (ischemic or hemorrhagic cere-
rovascular accident, cardiac event [including myocardial
nfarction and/or congestive heart failure], peripheral vascu-
ar events and other ischemic events) were recorded during
ollow-up. We  analyzed the predictor value of CKMB for car-
iovascular events.
tatistical  procedures
alues are expressed as the mean (SD) or median (IQR).
e established linear regression models for evaluating the
istribution of the studied variables according to CKMB lev-
ls. To assess the diagnosis value of the different cardiac
arkers we  used the receiving operator characteristics (ROC)
urve for each one. Correlations between cardiac markers
ere performed using Pearson test. Multivariate analysis was
erformed by Cox regression. Variables were analyzed and
nly those considered confounders were entered in the ﬁnal
ox regression model. Different models were used, including
KMB for its different values, in order to determine the best
ut-off to assess cardiovascular risk. Cardiovascular events
ere analyzed using Kaplan–Meier plots, and survival curves
ere compared using the log-rank test. We  used the integrated
iscrimination improvement (IDI), as described by Pencina
t al.14 to interpret the incremental value of CKMB ≥ 2 ng/mL
dded to a risk prediction model including age, sex, previous
eart disease, peripheral vascular disease, diabetes mellitus,
tproBNP and HsTnT. IDI is a measure of improvement in
odel performance and represents the difference between
iscrimination slopes of two competing models. We  calculated
he relative IDI, which expresses the relative increase in sepa-
ation of events and non-events from the separation achieved
n the base model (i.e., the difference in discrimination slopes
s expressed as a proportion of the discrimination slope of the
ase model).15 All statistical analyses were performed with3 6(1):51–56 53
the SPSS® 18.0 statistical package (Chicago, IL, USA). A p-value
<0.05 was considered statistically signiﬁcant.
Results
Baseline  characteristics  and  factors  associated  with
increased  levels
A total of 211 prevalent hemodialysis patients were included
in this study to be followed for 39 (19–56) months. One hundred
and twenty-three patients (58.3%) were male, with a median
age of 73 (60–80). Baseline characteristic are showed in Table 1.
The median value of CKMB was 1 (1–2) ng/mL, with the follow-
ing distribution: 13 patients (6.3%) have basal levels of 0 ng/mL,
121 (58.5) have 1 ng/mL, 56 (27.1%) have 2 ng/mL, 13 (6.3%) have
3 ng/dL and only 4 (1.9) have 4 ng/dL. In Table 2, baseline char-
acteristics are shown in the different strata according to CKMB
values. No patients exceeded the normal range of our lab-
oratory (0–4 ng/mL). Univariate analysis revealed that higher
levels of CKMB were associated to previous heart disease, dia-
betes mellitus, peripheral vascular disease and systolic and
diastolic dysfunction (data shown in Table 3).
Correlation  with  other  cardiac  biomarkers
Correlation between cardiac biomarkers showed a positive
and signiﬁcant one between CKMB and NtproBNP (0.163,Mean (standart deviation).
∗ Median (interquartile range). High sentivity troponin T (hsTnT),
Creatinekinase-MB(CK-MB), N-terminal prohormone of brain natri-
ureticpeptide (NT-proBNP), C- reactive protein (CRP).
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Table 2 – Descriptive of baseline characteristics according to CKMB values.
CKMB = 0 ng/mL
(n=13)
CKMB = 1 ng/mL
(n=121)
CKMB = 2 ng/mL
(n=56)
CKMB ≥ 3 ng/mL
(n=17)
P for trend
Age (years)* 77 (62-81) 75 (56-81) 73 (63-78) 66 (70-64) 0.096
Sex male (%) 53.8 57.0 60.7 76.5 0.072
Previous heart disease (%) 30.8 36.4 50.0  70.6 0.030
Diabetes mellitus (%) 15.4 28.9 37.5 52.9 0.013
Peripheral vascular disease(%) 23.1 24.8 41.1 41.2 0.027
Left ventricular hypertrophy (%)a 44.4 64.7 57.1 84.6 0.181
Systolic dysfunction (%)a 11.1 8.1 20 38.5 0.040
Diastolic dysfunction (%)a 30.8 27.1 25.7 53.8 0.019
Previous dialysis vintage (months)* 107 (38-132) 82 (46-128) 85 (31-148) 62 (40-122) 0.291
HsTnT (ng/L)* 71 (39-88) 50 (30-74) 67 (42-128) 89 (44-144) <0.001
Nt-proBNP (ng/L)* 6814 (3894-12466) 4112 (2159-14244) 7293 (2506-17008) 10524 (4265-20146) 0.020
CRP (mg/L)* 15.0 (6.5-27.5) 7.0 (3.0-14.5) 6.0 (4.0-12.0) 14.0 (6.0-22.0) 0.298
∗ Median (interquartile range).
a Percentage over the patients with a previous echocardiogram (166). Abbrev.: High sentivity troponin T (hsTnT), Creatinekinase-MB(CK-MB),
eactiN-terminal prohormone of brain natriureticpeptide (NT-proBNP), C- r
Cardiovascular  events  and  predictive  value  of  CKMB
A total of 94 cardiovascular events were recorded during the
follow up. Cardiac event was the most common event (79.8%),
followed by peripheral vascular disease (8.5%), cerebrovas-
cular event (6.4%). Diabetic patients did not show higher
incidence of cardiovascular events in our cohort (p = 0.3),
although they have a trend of higher prevalence of dia-
stolic dysfunction (p = 0.056). The area under the ROC curve
for cardiovascular events was greater for HsTnT (0.723) and
Nt-proBNP (0.688) than CKMB (0.587). CKMB levels were asso-
ciated to the development of cardiovascular events during
follow up [HR 1.46 95% CI (1.15–1.87), p = 0.002] as well as
the other factors shown in Table 3. In Fig. 1, the survival
Table 3 – Factors associated with cardiovascular events
during follow up (unadjusted Cox regression).
HR (95% CI) P
Age (years) 1.02 (1.01-1.03) 0.027
Sex (male) 1.11 (0.73-1.67) 0.619
Previous Heart Disease 4.99 (3.16-7.66) <0.001
Diabetes Mellitus 1.23 (0.81-1.88) 0.330
Peripheral vascular disease 1.53 (1.01-2.32) 0.049
Dialysis Vintage (per month) 1.00 (0.99-1.01) 0.825
Vascular access (autologus
ﬁstualae)*
0.96 (0.64-1.45) 0.860
Left ventricular hypertrophy 1.64 (0.94-2.85) 0.080
Systolic dysfunction 2.72 (1.52-4.85) 0.001
Diastolic dysfunction 2.59 (1.52-4.42) <0.001
CK-MB (ng/mL) 1.46 (1.15-1.87) 0.002
HsTnT ≥ 56 ng/L (ng/L) 2.52 (1.47-4.32) 0.001
Nt-proBNP (mcg/L) 1.01 (1.01-1.01) <0.001
CRP (mg/dL) 1.01 (0.96-1.07) 0.578
Abbreviations: HR (95% CI) = Hazard ratio (95% Conﬁdence interval).
(F/M)=(female/male). Creatinekinase-MB(CK-MB),  N-terminal prohor-
mone of brain natriureticpeptide (NT-proBNP),High sentivity troponin
T (hsTnT), C- reactive protein (CRP).
∗ Autologous vascular access has been codiﬁed as 0 and non-
autologous as 1.ve protein (CRP).
curve shows the association between cardiovascular events
and the different CKMB values conﬁrming that higher levels
condition worse prognosis (logRank 8.8, p = 0.01). Multivari-
ate Cox regression model adjusted for several cofounders and
variables showed that CKMB levels ≥2 ng/mL independently
increased cardiovascular risk in our cohort of hemodialysis
patients. A non-signiﬁcant trend was observed if the CKMB
cut-off was ≥1 ng/mL (Table 4).
IDI analysis was performed to assess the improvement in
risk discrimination of adding CKMB (≥2 ng/mL) to a cardiovas-
cular event risk prediction model including age, sex, previous
heart disease, peripheral vascular disease, diabetes mellitus,
NtproBNP and HsTnT. This analysis comprised all individ-
uals and used NtproBNP and HsTnT as dichotomous variables.
Adding CKMB resulted in 17% improved risk discrimination for
cardiovascular events (IDI 0.026 [0.004–0.053]; relative IDI 9.9%;
p = 0.04).
Discussion
Our study demonstrates that CK-MB is a useful marker
for stratifying cardiovascular risk in dialysis patients, even
in normal range values. Importantly for acute situations,
hemodialysis patients do not have basally elevated higher
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Fig. 1 – Kaplan–Meier plot illustrating cardiovascular events
and CKMB values.
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Table 4 – Predictor value of the different values of CK-MB for cardiovascular events during follow up (adjusted Cox
regression) alone and in combination with the other cardiac biomarkers.
HR (95% CI) P
CKMB = 0 (ng/mL) ref ref
CKMB ≥ 1 ng/mLa
- CKMB ≥ 1 ng/mL * NtproBNP ≥ 4994 ng/Lb
- CKMB ≥ 1 ng/mL * HsTnT ≥ 56 ng/Lb
- CKMB ≥ 1 ng/mL * NtproBNP ≥ 4994 ng/L * HsTnT ≥ 56 ng/Lb
2.20 (0.88-5.51)
2.84 (1.79-4.53)
1.98 (1.23-3.17)
2.71 (1.74-4.21)
0.092
<0.001
0.005
<0.001
CKMB ≥ 2 (ng/mL)a
- CKMB ≥ 2 ng/mL * NtproBNP ≥ 4994 ng/Lb
- CKMB ≥ 2 ng/mL * HsTnT ≥ 56 ng/Lb
- CKMB ≥ 2 ng/mL * NtproBNP ≥ 4994 ng/L * HsTnT ≥ 56 ng/Lb
1.63 (1.06-2.53)
3.01 (1.90-4.81)
1.82 (1.11-2.99)
3.24 (1.92-5.47)
0.027
<0.001
0.016
<0.001
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brain natriureticpeptide and high sentivity troponin T.
b Cox regression model adjusted for age, sex, previous heart disease,
evels, so this marker could be useful in the differential diag-
osis of chest pain as marker of acute ischemia. Supporting
his fact, and different from other cardiac markers, CKMB
oes not appear to be inﬂuenced by the dialysis, so its lev-
ls remain stable after and before.16 However, and although
KMB has a short half-life, its levels are correlated to HsTnT
nd NtproBNP and their values are associated to other car-
iovascular risk factors. One study conducted by McCullong
t al. that included 817 consecutive patients with chest pain,
hown that those with conﬁrmed acute myocardial infarction
AMI) suffer a CKMB rise irrespective of the renal function.17
uriously, in this study, those patients without ﬁnal diagno-
is of AMI  showed signiﬁcant different basal levels of CKMB
etween groups (inversely correlated with glomerular ﬁltra-
ion and maximum in dialysis patients), unlike those with ﬁnal
iagnosis of AMI.
The ﬁrst report regarding the inﬂuence of hemodialysis in
KMB levels was published in 1984 by Jaffe et al.18 In this
tudy that included 88 patients, authors demonstrated nor-
al  levels of CKMB for the most part of the studied sample.
lthough some authors differ in their opinions on this regard,
he CHANCE study conﬁrmed not only this situation but also
hat levels of CK-MB could be inﬂuenced by the presence of
istory of ischemic heart disease.19–22 Our results agree with
his ﬁnding, and with the association to age (we could only
emonstrate a trend with this value) and troponins. Cardio-
ascular risk factors as peripheral vascular disease, diabetes
ellitus and Nt-proBNP seem to be associated to CKMB, above
ll with values ≥3 ng/mL.
We assessed the predictive value of CKMB for cardiovas-
ular events. Our data suggests that CKMB ≥ 2 ng/mL give a
oor cardiovascular prognosis in dialysis patients. Results of
HANCE study agree with our results, showing an increased
isk of major cardiovascular events in those patients with
KMB ≥ 3 ng/mL, in a 2-year follow up.11
However, CKMB is not the only marker but the less stud-
ed in this regard, although it is cheap and easily applicable
n routine clinical. In adjusted multivariate analysis, those
atients with HsTnT and NtproBNP over the median and
KMB ≥ 2 ng/mL enhanced its cardiovascular risk more  than
hreefold, in comparison to CKMB ≥ 2 ng/mL alone. Several
tudies have found an association between cardiac markers
nd prognosis, and now we know that this situation reveals
 true clinical or subclinical cardiac damage.7,23 In fact, inheral vascular disease, diabetes mellitus, N-terminal prohormone of
heral vascular disease, diabetes mellitus.
our study, CKMB demonstrated an association with previous
heart disease and also with systolic and diastolic dysfunc-
tion. Previous published data has only been able to remark an
association to LVH in patients with renal function impairment.
The present study has some limitations. Firstly, the typi-
cal limitations of a retrospective design. Secondly, not all the
patients had a echocardiograph image  and they were per-
formed by different specialists. This bias was partially avoided
by the use of the same criteria for the deﬁnitions of each entity
(systolic and diastolic dysfunction and LVH). Thirdly, vascular
calciﬁcations were not assessed as recommended in recent
guidelines.24 Lastly, the study was performed in one center,
and results must be conﬁrmed in bigger sample size.
In conclusion, CKMB is a good marker for stratifying car-
diovascular risk in hemodialysis patients even in the normal
range of their values. We recommend measuring several car-
diac markers, at least two, in order to get better predictive
values. As basal levels of CKMB are not elevated in these
patients, further studies are required to conﬁrm their value
in acute coronary syndromes.
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